{"entity":{"id":"nct07227636","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","aka":[],"tldr":"A phase 2 trial of botensilimab and balstilimab in colorectal cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy is a phase 2, randomised interventional study registered as NCT07227636 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 284 participants, started 2025-11-07 and due to reach its primary completion in 2030-11. Interventions recorded: Botensilimab; Balstilimab; Placebo. Conditions listed: Colorectal Cancer; Rectal Cancer. Primary outcome: Rate of ctDNA clearance (Cohort 1a); Rate of ctDNA clearance (Cohort 1b); Recurrence-free survival (RFS) (Cohort 2a). Colorectal eligibility wording from the registry: \"* Histologically- or cytologically- confirmed colorectal cancer\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07227636","url":"https://clinicaltrials.gov/study/NCT07227636"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","mrd-testing"],"targets":[],"drugs":["botensilimab","balstilimab"],"companies":["agenus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07227636","phase":"2","setting":"Phase II Study of Adjuvant Botensilimab in Combination With Balstilimab in Patients With Colorectal Cancer and Persistent Circulating Tumor DNA Following Surgery and Chemotherapy","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":284,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07227636/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/"},{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/"}],"company":[{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}